Psychedelic-assisted psychotherapy: The Australian and general practice perspective
Australian Journal of General Practice February 1, 2026 Anthony Helman 1 citation
Since July 2023, Australia has made two psychedelic medicines available in the private sector for psychotherapeutic treatment, allowing general practitioners to refer patients with treatment-resistant depression or PTSD. These medicines can help patients access subconscious emotions, thoughts, beliefs, and traumatic memories that are otherwise difficult to reach. Meta-analyses of clinical trials have shown substantial effect sizes, though not everyone is suited to or will respond to this treatment. GPs can expect to play a role in referring and supporting patients, as ongoing trials continue to clarify the indications, efficacy, and safety of psychedelic therapy.